<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37446298</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>13</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>05</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Altered Hippocampal and Striatal Expression of Endothelial Markers and VIP/PACAP Neuropeptides in a Mouse Model of Systemic Lupus Erythematosus.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11118</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms241311118</ELocationID><Abstract><AbstractText>Neuropsychiatric systemic lupus erythematosus (NPSLE) is one of the most common and severe manifestations of lupus; however, its pathogenesis is still poorly understood. While there is sparse evidence suggesting that the ongoing autoimmunity may trigger pathogenic changes to the central nervous system (CNS) microvasculature, culminating in inflammatory/ischemic damage, further evidence is still needed. In this study, we used the spontaneous mouse model of SLE (NZBWF1 mice) to investigate the expression of genes and proteins associated with endothelial (dys)function: tissue and urokinase plasminogen activators (tPA and uPA), intercellular and vascular adhesion molecules 1 (ICAM-1 and VCAM-1), brain derived neurotrophic factor (BDNF), endothelial nitric oxide synthase (eNOS) and Kr&#xfc;ppel-like factor 4 (KLF4) and neuroprotection/immune modulation: pituitary adenylate cyclase-activating peptide (PACAP), vasoactive intestinal peptide (VIP), PACAP receptor (PAC1), VIP receptors 1 and 2 (VPAC1 and VPAC2). Analyses were carried out both in the hippocampus and striatum of SLE mice of two different age groups (2 and 7 months old), since age correlates with disease severity. In the hippocampus, we identified a gene/protein expression profile indicative of mild endothelial dysfunction, which increased in severity in aged SLE mice. These alterations were paralleled by moderate alterations in the expression of VIP, PACAP and related receptors. In contrast, we report a robust upregulation of endothelial activation markers in the striatum of both young and aged mice, concurrent with significant induction of the VIP/PACAP system. These data identify molecular signatures of endothelial alterations in the hippocampus and striatum of NZBWF1 mice, which are accompanied by a heightened expression of endogenous protective/immune-modulatory neuropeptides. Collectively, our results support the idea that NPSLE may cause alterations of the CNS micro-vascular compartment that cannot be effectively counteracted by the endogenous activity of the neuropeptides PACAP and VIP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jayden</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0000-5583-0579</Identifier><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Science, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomas Broome</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-5444-0920</Identifier><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Science, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jansen</LastName><ForeName>Margo Iris</ForeName><Initials>MI</Initials><Identifier Source="ORCID">0000-0003-0721-4055</Identifier><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Science, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandwie</LastName><ForeName>Mawj</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-4165-4276</Identifier><AffiliationInfo><Affiliation>Gene Therapy Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney and Sydney Children's Hospitals Network, Westmead, NSW 2145, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Logan</LastName><ForeName>Grant J</ForeName><Initials>GJ</Initials><Identifier Source="ORCID">0000-0001-9365-342X</Identifier><AffiliationInfo><Affiliation>Gene Therapy Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney and Sydney Children's Hospitals Network, Westmead, NSW 2145, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marzagalli</LastName><ForeName>Rubina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Science, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Musumeci</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8260-8890</Identifier><AffiliationInfo><Affiliation>Department of Biomedical and Biotechnological Sciences, Anatomy, Histology and Movement Sciences Section, School of Medicine, University of Catania, 95124 Catania, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castorina</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7037-759X</Identifier><AffiliationInfo><Affiliation>Laboratory of Cellular and Molecular Neuroscience (LCMN), School of Life Science, Faculty of Science, University of Technology Sydney, Sydney, NSW 2007, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PG2019449</GrantID><Agency>Rebecca L. Cooper Medical Research Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>37221-79-7</RegistryNumber><NameOfSubstance UI="D014660">Vasoactive Intestinal Peptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051219">Pituitary Adenylate Cyclase-Activating Polypeptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051237">Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051238">Receptors, Vasoactive Intestinal Polypeptide, Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051239">Receptors, Vasoactive Intestinal Peptide, Type II</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014660" MajorTopicYN="Y">Vasoactive Intestinal Peptide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051219" MajorTopicYN="N">Pituitary Adenylate Cyclase-Activating Polypeptide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051237" MajorTopicYN="N">Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051238" MajorTopicYN="N">Receptors, Vasoactive Intestinal Polypeptide, Type I</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051239" MajorTopicYN="N">Receptors, Vasoactive Intestinal Peptide, Type II</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NZBWF1 mice</Keyword><Keyword MajorTopicYN="N">PACAP</Keyword><Keyword MajorTopicYN="N">VIP</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">endothelial dysfunction</Keyword><Keyword MajorTopicYN="N">hippocampus</Keyword><Keyword MajorTopicYN="N">neuropeptides</Keyword><Keyword MajorTopicYN="N">neuropsychiatric systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">striatum</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>13</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>1</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37446298</ArticleId><ArticleId IdType="pmc">PMC10342033</ArticleId><ArticleId IdType="doi">10.3390/ijms241311118</ArticleId><ArticleId IdType="pii">ijms241311118</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mok C.C., Lau C.S. Pathogenesis of systemic lupus erythematosus. J. Clin. Pathol. 2003;56:481&#x2013;490. doi: 10.1136/jcp.56.7.481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jcp.56.7.481</ArticleId><ArticleId IdType="pmc">PMC1769989</ArticleId><ArticleId IdType="pubmed">12835292</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter E.E., Barr S.G., Clarke A.E. The global burden of SLE: Prevalence, health disparities and socioeconomic impact. Nat. Rev. Rheumatol. 2016;12:605&#x2013;620. doi: 10.1038/nrrheum.2016.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.137</ArticleId><ArticleId IdType="pubmed">27558659</ArticleId></ArticleIdList></Reference><Reference><Citation>Cie&#x15b;lik P., Hrycek A., K&#x142;uci&#x144;ski P. Vasculopathy and vasculitis in systemic lupus erythematosus. Pol. Arch. Med. Wewn. 2008;118:57&#x2013;63. doi: 10.20452/pamw.306.</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.306</ArticleId><ArticleId IdType="pubmed">18405174</ArticleId></ArticleIdList></Reference><Reference><Citation>Popescu A., Kao A.H. Neuropsychiatric systemic lupus erythematosus. Curr. Neuropharmacol. 2011;9:449&#x2013;457. doi: 10.2174/157015911796557984.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157015911796557984</ArticleId><ArticleId IdType="pmc">PMC3151599</ArticleId><ArticleId IdType="pubmed">22379459</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahn G.Y., Kim D., Won S., Song S.T., Jeong H.J., Sohn I.W., Lee S., Joo Y.B., Bae S.C. Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: A prospective, single-center study. Lupus. 2018;27:1338&#x2013;1347. doi: 10.1177/0961203318772021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318772021</ArticleId><ArticleId IdType="pubmed">29688144</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscal E., Brey R.L. Neurologic manifestations of systemic lupus erythematosus in children and adults. Neurol. Clin. 2010;28:61&#x2013;73. doi: 10.1016/j.ncl.2009.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2009.09.004</ArticleId><ArticleId IdType="pmc">PMC2981505</ArticleId><ArticleId IdType="pubmed">19932376</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibbitt W.L., Jr., Brooks W.M., Kornfeld M., Hart B.L., Bankhurst A.D., Roldan C.A. Magnetic resonance imaging and brain histopathology in neuropsychiatric systemic lupus erythematosus. Semin. Arthritis Rheum. 2010;40:32&#x2013;52. doi: 10.1016/j.semarthrit.2009.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2009.08.005</ArticleId><ArticleId IdType="pmc">PMC3586567</ArticleId><ArticleId IdType="pubmed">19880162</ArticleId></ArticleIdList></Reference><Reference><Citation>Zirkzee E.J., Huizinga T.W., Bollen E.L., van Buchem M.A., Middelkoop H.A., van der Wee N.J., le Cessie S., Steup-Beekman G.M. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE) Lupus. 2014;23:31&#x2013;38. doi: 10.1177/0961203313512540.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313512540</ArticleId><ArticleId IdType="pubmed">24243776</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng X., Pan W., Liu L., Wu M., Ding F., Hu H., Ding X., Wei H., Zou Y., Qian X., et al. Prognosis for Hospitalized Patients with Systemic Lupus Erythematosus in China: 5-Year Update of the Jiangsu Cohort. PLoS ONE. 2016;11:e0168619. doi: 10.1371/journal.pone.0168619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0168619</ArticleId><ArticleId IdType="pmc">PMC5193352</ArticleId><ArticleId IdType="pubmed">28030595</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulinello M., Wen J., Putterman C. Neuropsychiatric Symptoms in Lupus. Psychiatr. Ann. 2012;42:322&#x2013;328. doi: 10.3928/00485713-20120906-05.</Citation><ArticleIdList><ArticleId IdType="doi">10.3928/00485713-20120906-05</ArticleId><ArticleId IdType="pmc">PMC4302271</ArticleId><ArticleId IdType="pubmed">25620816</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih Y.C., Ou Y.H., Chang S.W., Lin C.M. A challenging case of neuropsychiatric systematic lupus erythematosus with recurrent antiphospholipid- related stroke: A case report and literature review. Neurol. Int. 2019;11:8182. doi: 10.4081/ni.2019.8182.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/ni.2019.8182</ArticleId><ArticleId IdType="pmc">PMC6763748</ArticleId><ArticleId IdType="pubmed">31579149</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Xiang X., Sun J., Liu S., Liu Y., Feng L., Li C., Li Z. Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: A real world single center study. Mod. Rheumatol. 2020;30:321&#x2013;326. doi: 10.1080/14397595.2019.1589912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2019.1589912</ArticleId><ArticleId IdType="pubmed">30836042</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg R. Why can&#x2019;t we find a new treatment for SLE? J. Autoimmun. 2009;32:223&#x2013;230. doi: 10.1016/j.jaut.2009.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2009.02.006</ArticleId><ArticleId IdType="pmc">PMC2699771</ArticleId><ArticleId IdType="pubmed">19329279</ArticleId></ArticleIdList></Reference><Reference><Citation>Maidhof W., Hilas O. Lupus: An overview of the disease and management options. Pharm. Ther. 2012;37:240&#x2013;249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3351863</ArticleId><ArticleId IdType="pubmed">22593636</ArticleId></ArticleIdList></Reference><Reference><Citation>Burbach J.P. What are neuropeptides? Methods Mol. Biol. 2011;789:1&#x2013;36. doi: 10.1007/978-1-61779-310-3_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-61779-310-3_1</ArticleId><ArticleId IdType="pubmed">21922398</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganea D., Hooper K.M., Kong W. The neuropeptide vasoactive intestinal peptide: Direct effects on immune cells and involvement in inflammatory and autoimmune diseases. Acta Physiol. 2015;213:442&#x2013;452. doi: 10.1111/apha.12427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.12427</ArticleId><ArticleId IdType="pmc">PMC4484298</ArticleId><ArticleId IdType="pubmed">25422088</ArticleId></ArticleIdList></Reference><Reference><Citation>Castorina A., Vogiatzis M., Kang J.W.M., Keay K.A. PACAP and VIP expression in the periaqueductal grey of the rat following sciatic nerve constriction injury. Neuropeptides. 2019;74:60&#x2013;69. doi: 10.1016/j.npep.2018.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.npep.2018.12.002</ArticleId><ArticleId IdType="pubmed">30579677</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirabayashi T., Nakamachi T., Shioda S. Discovery of PACAP and its receptors in the brain. J. Headache Pain. 2018;19:28. doi: 10.1186/s10194-018-0855-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s10194-018-0855-1</ArticleId><ArticleId IdType="pmc">PMC5884755</ArticleId><ArticleId IdType="pubmed">29619773</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaudry D., Falluel-Morel A., Bourgault S., Basille M., Burel D., Wurtz O., Fournier A., Chow B.K., Hashimoto H., Galas L., et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol. Rev. 2009;61:283&#x2013;357. doi: 10.1124/pr.109.001370.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.109.001370</ArticleId><ArticleId IdType="pubmed">19805477</ArticleId></ArticleIdList></Reference><Reference><Citation>Karunia J., Niaz A., Mandwie M., Thomas Broome S., Keay K.A., Waschek J.A., Al-Badri G., Castorina A. PACAP and VIP Modulate LPS-Induced Microglial Activation and Trigger Distinct Phenotypic Changes in Murine BV2 Microglial Cells. Int. J. Mol. Sci. 2021;22:10947. doi: 10.3390/ijms222010947.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222010947</ArticleId><ArticleId IdType="pmc">PMC8535941</ArticleId><ArticleId IdType="pubmed">34681607</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas Broome S., Musumeci G., Castorina A. Doxycycline and Minocycline Act as Positive Allosteric Modulators of the PAC1 Receptor and Induce Plasminogen Activators in RT4 Schwann Cells. Appl. Sci. 2021;11:7673. doi: 10.3390/app11167673.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/app11167673</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen M.I., Broome S.T., Castorina A. Targeting the neurological comorbidities of multiple sclerosis: The beneficial effects of VIP and PACAP neuropeptides. J. Integr. Neurosci. 2022;21:33. doi: 10.31083/j.jin2101033.</Citation><ArticleIdList><ArticleId IdType="doi">10.31083/j.jin2101033</ArticleId><ArticleId IdType="pubmed">35164469</ArticleId></ArticleIdList></Reference><Reference><Citation>Jozwiak-Bebenista M., Kowalczyk E. Neuroleptic Drugs and PACAP Differentially Affect the mRNA Expression of Genes Encoding PAC1/VPAC Type Receptors. Neurochem. Res. 2017;42:943&#x2013;952. doi: 10.1007/s11064-016-2127-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-016-2127-2</ArticleId><ArticleId IdType="pmc">PMC5375968</ArticleId><ArticleId IdType="pubmed">27900577</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang W., Wang H., Li Y.S., Luo W. Role of vasoactive intestinal peptide in osteoarthritis. J. Biomed. Sci. 2016;23:63. doi: 10.1186/s12929-016-0280-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-016-0280-1</ArticleId><ArticleId IdType="pmc">PMC4995623</ArticleId><ArticleId IdType="pubmed">27553659</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez C., Abad C., Delgado M., Arranz A., Juarranz M.G., Rodriguez-Henche N., Brabet P., Leceta J., Gomariz R.P. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc. Natl. Acad. Sci. USA. 2002;99:1053&#x2013;1058. doi: 10.1073/pnas.012367999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.012367999</ArticleId><ArticleId IdType="pmc">PMC117428</ArticleId><ArticleId IdType="pubmed">11792830</ArticleId></ArticleIdList></Reference><Reference><Citation>Delgado M., Abad C., Martinez C., Juarranz M.G., Arranz A., Gomariz R.P., Leceta J. Vasoactive intestinal peptide in the immune system: Potential therapeutic role in inflammatory and autoimmune diseases. J. Mol. Med. 2002;80:16&#x2013;24. doi: 10.1007/s00109-001-0291-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00109-001-0291-5</ArticleId><ArticleId IdType="pubmed">11862320</ArticleId></ArticleIdList></Reference><Reference><Citation>Castorina A., Giunta S., Mazzone V., Cardile V., D&#x2019;Agata V. Effects of PACAP and VIP on hyperglycemia-induced proliferation in murine microvascular endothelial cells. Peptides. 2010;31:2276&#x2013;2283. doi: 10.1016/j.peptides.2010.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2010.08.013</ArticleId><ArticleId IdType="pubmed">20800633</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund A.M., Hannibal J. Localization of the neuropeptides pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal peptide, and their receptors in the basal brain blood vessels and trigeminal ganglion of the mouse CNS; an immunohistochemical study. Front. Neuroanat. 2022;16:991403. doi: 10.3389/fnana.2022.991403.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnana.2022.991403</ArticleId><ArticleId IdType="pmc">PMC9643199</ArticleId><ArticleId IdType="pubmed">36387999</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncharov N.V., Nadeev A.D., Jenkins R.O., Avdonin P.V. Markers and Biomarkers of Endothelium: When Something Is Rotten in the State. Oxid. Med. Cell Longev. 2017;2017:9759735. doi: 10.1155/2017/9759735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/9759735</ArticleId><ArticleId IdType="pmc">PMC5733214</ArticleId><ArticleId IdType="pubmed">29333215</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobik A., Tkachuk V. Metalloproteinases and plasminogen activators in vessel remodeling. Curr. Hypertens. Rep. 2003;5:466&#x2013;472. doi: 10.1007/s11906-003-0054-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-003-0054-5</ArticleId><ArticleId IdType="pubmed">14594565</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Shi Q.-D., Song T.-B., Feng G.-F., Zang W.-J., Zong C.-H., Chang L. Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro. Peptides. 2013;42:105&#x2013;111. doi: 10.1016/j.peptides.2013.01.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.peptides.2013.01.007</ArticleId><ArticleId IdType="pubmed">23340020</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank P.G., Lisanti M.P. ICAM-1: Role in inflammation and in the regulation of vascular permeability. Am. J. Physiol. Heart Circ. Physiol. 2008;295:H926&#x2013;H927. doi: 10.1152/ajpheart.00779.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00779.2008</ArticleId><ArticleId IdType="pmc">PMC2544488</ArticleId><ArticleId IdType="pubmed">18689494</ArticleId></ArticleIdList></Reference><Reference><Citation>Kong D.H., Kim Y.K., Kim M.R., Jang J.H., Lee S. Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in Immunological Disorders and Cancer. Int. J. Mol. Sci. 2018;19:1057. doi: 10.3390/ijms19041057.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19041057</ArticleId><ArticleId IdType="pmc">PMC5979609</ArticleId><ArticleId IdType="pubmed">29614819</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaleb A.M., Yang V.W. Kr&#xfc;ppel-like factor 4 (KLF4): What we currently know. Gene. 2017;611:27&#x2013;37. doi: 10.1016/j.gene.2017.02.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2017.02.025</ArticleId><ArticleId IdType="pmc">PMC5391259</ArticleId><ArticleId IdType="pubmed">28237823</ArticleId></ArticleIdList></Reference><Reference><Citation>Heiss C., Rodriguez-Mateos A., Kelm M. Central role of eNOS in the maintenance of endothelial homeostasis. Antioxid. Redox Signal. 2015;22:1230&#x2013;1242. doi: 10.1089/ars.2014.6158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2014.6158</ArticleId><ArticleId IdType="pmc">PMC4410282</ArticleId><ArticleId IdType="pubmed">25330054</ArticleId></ArticleIdList></Reference><Reference><Citation>Napolitano F., Montuori N. Role of Plasminogen Activation System in Platelet Pathophysiology: Emerging Concepts for Translational Applications. Int. J. Mol. Sci. 2022;23:6065. doi: 10.3390/ijms23116065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23116065</ArticleId><ArticleId IdType="pmc">PMC9181697</ArticleId><ArticleId IdType="pubmed">35682744</ArticleId></ArticleIdList></Reference><Reference><Citation>Stepanova V., Jayaraman P.S., Zaitsev S.V., Lebedeva T., Bdeir K., Kershaw R., Holman K.R., Parfyonova Y.V., Semina E.V., Beloglazova I.B., et al. Urokinase-type Plasminogen Activator (uPA) Promotes Angiogenesis by Attenuating Proline-rich Homeodomain Protein (PRH) Transcription Factor Activity and De-repressing Vascular Endothelial Growth Factor (VEGF) Receptor Expression. J. Biol. Chem. 2016;291:15029&#x2013;15045. doi: 10.1074/jbc.M115.678490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.678490</ArticleId><ArticleId IdType="pmc">PMC4946921</ArticleId><ArticleId IdType="pubmed">27151212</ArticleId></ArticleIdList></Reference><Reference><Citation>Crookston K.P., Sibbitt W.L., Jr., Chandler W.L., Qualls C.R., Roldan C.A. Circulating microparticles in neuropsychiatric systemic lupus erythematosus. Int. J. Rheum. Dis. 2013;16:72&#x2013;80. doi: 10.1111/1756-185x.12026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185x.12026</ArticleId><ArticleId IdType="pubmed">23441775</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang P.T., Teng H.K., Zaitsev E., Woo N.T., Sakata K., Zhen S., Teng K.K., Yung W.H., Hempstead B.L., Lu B. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science. 2004;306:487&#x2013;491. doi: 10.1126/science.1100135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1100135</ArticleId><ArticleId IdType="pubmed">15486301</ArticleId></ArticleIdList></Reference><Reference><Citation>Castorina A., D&#x2019;Amico A., Scuderi S., Leggio G., Drago F., D&#x2019;Agata V. Dopamine D3 receptor deletion increases tissue plasminogen activator (tPA) activity in prefrontal cortex and hippocampus. Neuroscience. 2013;250:546&#x2013;556. doi: 10.1016/j.neuroscience.2013.07.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2013.07.053</ArticleId><ArticleId IdType="pubmed">23906635</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen A., Xiong L.J., Tong Y., Mao M. The neuroprotective roles of BDNF in hypoxic ischemic brain injury. Biomed. Rep. 2013;1:167&#x2013;176. doi: 10.3892/br.2012.48.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/br.2012.48</ArticleId><ArticleId IdType="pmc">PMC3956206</ArticleId><ArticleId IdType="pubmed">24648914</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng Y., Chopp M., Zhang Y., Liu Z., An A., Mahmood A., Xiong Y. Subacute intranasal administration of tissue plasminogen activator promotes neuroplasticity and improves functional recovery following traumatic brain injury in rats. PLoS ONE. 2014;9:e106238. doi: 10.1371/journal.pone.0106238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0106238</ArticleId><ArticleId IdType="pmc">PMC4153585</ArticleId><ArticleId IdType="pubmed">25184365</ArticleId></ArticleIdList></Reference><Reference><Citation>Iacobas D.A., Wen J., Iacobas S., Putterman C., Schwartz N. TWEAKing the Hippocampus: The Effects of TWEAK on the Genomic Fabric of the Hippocampus in a Neuropsychiatric Lupus Mouse Model. Genes. 2021;12:1172. doi: 10.3390/genes12081172.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes12081172</ArticleId><ArticleId IdType="pmc">PMC8392718</ArticleId><ArticleId IdType="pubmed">34440346</ArticleId></ArticleIdList></Reference><Reference><Citation>Budhram A., Butendieck R.R., Duarte-Garcia A., Brinjikji W., Zalewski N.L. Striatal Encephalitis: Potential Inflammatory Vasculopathy in Systemic Lupus Erythematosus. Can. J. Neurol. Sci. 2021;48:415&#x2013;416. doi: 10.1017/cjn.2020.198.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/cjn.2020.198</ArticleId><ArticleId IdType="pubmed">32912371</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz N., Stock A.D., Putterman C. Neuropsychiatric lupus: New mechanistic insights and future treatment directions. Nat. Rev. Rheumatol. 2019;15:137&#x2013;152. doi: 10.1038/s41584-018-0156-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-018-0156-8</ArticleId><ArticleId IdType="pmc">PMC8023338</ArticleId><ArticleId IdType="pubmed">30659245</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L., Hu K. Tissue plasminogen activator and inflammation: From phenotype to signaling mechanisms. Am. J. Clin. Exp. Immunol. 2014;3:30&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960759</ArticleId><ArticleId IdType="pubmed">24660119</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D., Lian D., Wu J., Liu Y., Zhu M., Sun J., He D., Li L. Brain-derived neurotrophic factor reduces inflammation and hippocampal apoptosis in experimental Streptococcus pneumoniae meningitis. J. Neuroinflamm. 2017;14:156. doi: 10.1186/s12974-017-0930-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-017-0930-6</ArticleId><ArticleId IdType="pmc">PMC5545027</ArticleId><ArticleId IdType="pubmed">28778220</ArticleId></ArticleIdList></Reference><Reference><Citation>Sangwung P., Zhou G., Nayak L., Chan E.R., Kumar S., Kang D.W., Zhang R., Liao X., Lu Y., Sugi K., et al. KLF2 and KLF4 control endothelial identity and vascular integrity. JCI Insight. 2017;2:e91700. doi: 10.1172/jci.insight.91700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.91700</ArticleId><ArticleId IdType="pmc">PMC5313061</ArticleId><ArticleId IdType="pubmed">28239661</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H., Zhu Y., Li Y., Ding X., Ma W., Han X., Wang B. BDNF-mediated mitophagy alleviates high-glucose-induced brain microvascular endothelial cell injury. Apoptosis. 2019;24:511&#x2013;528. doi: 10.1007/s10495-019-01535-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10495-019-01535-x</ArticleId><ArticleId IdType="pubmed">30877409</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson L.L., Bilbo S.D. Chemokines and the hippocampus: A new perspective on hippocampal plasticity and vulnerability. Brain Behav. Immun. 2013;30:186&#x2013;194. doi: 10.1016/j.bbi.2013.01.077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2013.01.077</ArticleId><ArticleId IdType="pubmed">23376170</ArticleId></ArticleIdList></Reference><Reference><Citation>Small S.A. Isolating pathogenic mechanisms embedded within the hippocampal circuit through regional vulnerability. Neuron. 2014;84:32&#x2013;39. doi: 10.1016/j.neuron.2014.08.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.08.030</ArticleId><ArticleId IdType="pmc">PMC4185396</ArticleId><ArticleId IdType="pubmed">25277453</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelley B.P., Corrigan J.J., Patel S.C., Griffith B.D. Neuropsychiatric Lupus with Antibody-Mediated Striatal Encephalitis. AJNR Am. J. Neuroradiol. 2018;39:2263&#x2013;2269. doi: 10.3174/ajnr.A5842.</Citation><ArticleIdList><ArticleId IdType="doi">10.3174/ajnr.A5842</ArticleId><ArticleId IdType="pmc">PMC7655406</ArticleId><ArticleId IdType="pubmed">30467216</ArticleId></ArticleIdList></Reference><Reference><Citation>Raventhiranathan N., Hussien A.R., Mirchia K., Swarnkar A., Mangla R. Striatal dominant lupus encephalitis-Is it vasculitis or an autoimmune process? Literature review &amp; new case report with vessel wall imaging. Radiol. Case Rep. 2022;17:1205&#x2013;1210. doi: 10.1016/j.radcr.2022.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.radcr.2022.01.002</ArticleId><ArticleId IdType="pmc">PMC8829497</ArticleId><ArticleId IdType="pubmed">35169429</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchida H., Matsushita Y., Ueda H. Epigenetic regulation of BDNF expression in the primary sensory neurons after peripheral nerve injury: Implications in the development of neuropathic pain. Neuroscience. 2013;240:147&#x2013;154. doi: 10.1016/j.neuroscience.2013.02.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2013.02.053</ArticleId><ArticleId IdType="pubmed">23466809</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayas A., Hummel V., Kallmann B.A., Karch C., Toyka K.V., Rieckmann P. Human cerebral endothelial cells are a potential source for bioactive BDNF. Cytokine. 2002;19:55&#x2013;58. doi: 10.1006/cyto.2002.0892.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cyto.2002.0892</ArticleId><ArticleId IdType="pubmed">12182839</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Kastner R., Freund T.F. Selective vulnerability of the hippocampus in brain ischemia. Neuroscience. 1991;40:599&#x2013;636. doi: 10.1016/0306-4522(91)90001-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(91)90001-5</ArticleId><ArticleId IdType="pubmed">1676492</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt-Kastner R. Genomic approach to selective vulnerability of the hippocampus in brain ischemia-hypoxia. Neuroscience. 2015;309:259&#x2013;279. doi: 10.1016/j.neuroscience.2015.08.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2015.08.034</ArticleId><ArticleId IdType="pubmed">26383255</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrachi M., Anderson E., Carroll K.R., Tehrani N., Volpe B.T., Diamond B. Cognitive dysfunction in SLE: An understudied clinical manifestation. J. Autoimmun. 2022;132:102911. doi: 10.1016/j.jaut.2022.102911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2022.102911</ArticleId><ArticleId IdType="pubmed">36127204</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xf6;rstermann U., Sessa W.C. Nitric oxide synthases: Regulation and function. Eur. Heart J. 2012;33:829&#x2013;837. doi: 10.1093/eurheartj/ehr304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehr304</ArticleId><ArticleId IdType="pmc">PMC3345541</ArticleId><ArticleId IdType="pubmed">21890489</ArticleId></ArticleIdList></Reference><Reference><Citation>Banoujaafar H., Monnier A., Pernet N., Quiri&#xe9; A., Garnier P., Prigent-Tessier A., Marie C. Brain BDNF levels are dependent on cerebrovascular endothelium-derived nitric oxide. Eur. J. Neurosci. 2016;44:2226&#x2013;2235. doi: 10.1111/ejn.13301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ejn.13301</ArticleId><ArticleId IdType="pubmed">27306299</ArticleId></ArticleIdList></Reference><Reference><Citation>Li S.T., Pan J., Hua X.M., Liu H., Shen S., Liu J.F., Li B., Tao B.B., Ge X.L., Wang X.H., et al. Endothelial nitric oxide synthase protects neurons against ischemic injury through regulation of brain-derived neurotrophic factor expression. CNS Neurosci. Ther. 2014;20:154&#x2013;164. doi: 10.1111/cns.12182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cns.12182</ArticleId><ArticleId IdType="pmc">PMC6493204</ArticleId><ArticleId IdType="pubmed">24397751</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen D., Rijnink E.C., Nabuurs R.J., Steup-Beekman G.M., Versluis M.J., Emmer B.J., Zandbergen M., van Buchem M.A., Allaart C.F., Wolterbeek R., et al. Brain histopathology in patients with systemic lupus erythematosus: Identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology. 2017;56:77&#x2013;86. doi: 10.1093/rheumatology/kew341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew341</ArticleId><ArticleId IdType="pubmed">28028157</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y.V., Abad C., Wang Y., Lopez R., Waschek J. VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses. Brain Behav. Immun. 2015;44:167&#x2013;175. doi: 10.1016/j.bbi.2014.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2014.09.020</ArticleId><ArticleId IdType="pmc">PMC4275378</ArticleId><ArticleId IdType="pubmed">25305591</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Wang Z., Zhang S., Wu Y., Zhang L., Zhao J., Wang Q., Tian X., Li M., Zeng X. Progress in the Pathogenesis and Treatment of Neuropsychiatric Systemic Lupus Erythematosus. J. Clin. Med. 2022;11:4955. doi: 10.3390/jcm11174955.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11174955</ArticleId><ArticleId IdType="pmc">PMC9456588</ArticleId><ArticleId IdType="pubmed">36078885</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandwie M., Karunia J., Niaz A., Keay K.A., Musumeci G., Rennie C., McGrath K., Al-Badri G., Castorina A. Metformin Treatment Attenuates Brain Inflammation and Rescues PACAP/VIP Neuropeptide Alterations in Mice Fed a High-Fat Diet. Int. J. Mol. Sci. 2021;22:13660. doi: 10.3390/ijms222413660.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222413660</ArticleId><ArticleId IdType="pmc">PMC8706124</ArticleId><ArticleId IdType="pubmed">34948457</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo L.M., Rizzu P., Francescatto M., Vitezic M., Leday G.G.R., Sanchez J.S., Khamis A., Takahashi H., van de Berg W.D.J., Medvedeva Y.A., et al. Regional differences in gene expression and promoter usage in aged human brains. Neurobiol. Aging. 2013;34:1825&#x2013;1836. doi: 10.1016/j.neurobiolaging.2013.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.01.005</ArticleId><ArticleId IdType="pubmed">23428183</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkes C.A., Gatherer M., Sharp M.M., Dorr A., Yuen H.M., Kalaria R., Weller R.O., Carare R.O. Regional differences in the morphological and functional effects of aging on cerebral basement membranes and perivascular drainage of amyloid-&#x3b2; from the mouse brain. Aging Cell. 2013;12:224&#x2013;236. doi: 10.1111/acel.12045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acel.12045</ArticleId><ArticleId IdType="pubmed">23413811</ArticleId></ArticleIdList></Reference><Reference><Citation>Tzang B.S., Hsu T.C., Chen T.Y., Huang C.Y., Li S.L., Kao S.H. Cystamine ameliorates ventricular hypertrophy associated with modulation of IL-6-mediated signaling in lupus-prone mice. Life Sci. 2013;92:719&#x2013;726. doi: 10.1016/j.lfs.2013.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2013.01.027</ArticleId><ArticleId IdType="pubmed">23399703</ArticleId></ArticleIdList></Reference><Reference><Citation>Paxinos G., Franklin K.B. Paxinos and Franklin&#x2019;s the Mouse Brain in Stereotaxic Coordinates. Academic Press; Cambridge, MA, USA: 2019.</Citation></Reference><Reference><Citation>Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008;3:1101&#x2013;1108. doi: 10.1038/nprot.2008.73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nprot.2008.73</ArticleId><ArticleId IdType="pubmed">18546601</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy J.G., McElhaney J.E., Verschoor C.P. Reliable reference genes for the quantification of mRNA in human T-cells and PBMCs stimulated with live influenza virus. BMC Immunol. 2020;21:4. doi: 10.1186/s12865-020-0334-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-020-0334-8</ArticleId><ArticleId IdType="pmc">PMC6995044</ArticleId><ArticleId IdType="pubmed">32005148</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucolo C., Leggio G.M., Maltese A., Castorina A., D&#x2019;Agata V., Drago F. Dopamine-(3) receptor modulates intraocular pressure: Implications for glaucoma. Biochem. Pharmacol. 2012;83:680&#x2013;686. doi: 10.1016/j.bcp.2011.11.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2011.11.031</ArticleId><ArticleId IdType="pubmed">22178719</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>